From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
With a first-in-class oral treatment approved, atopic dermatitis patients gain a novel option for disease management and improved …
Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
New partnerships in real-time genomics promise faster, more accurate diagnoses for pediatric rare diseases.
A promising vaccine candidate advances efforts to combat neglected tropical diseases with mRNA innovation.
Next-generation gene editing powers new hope for hard-to-treat solid tumors in early human trials.
A pivotal step forward for Duchenne families as gene therapy shows promise to transform neuromuscular care.
A historic breakthrough as the first CRISPR-based gene-editing therapy gains FDA approval, offering new hope for sickle cell …
ExoGene’s novel delivery platform earns RMAT status for its lead candidate EXG-401, targeting neuroinflammation and motor neuron survival …
Already a subscriber? Log in